ABSTRACT
INTRODUCTION
Mitral valve prolapse (MVP) is a common valvulopathy affecting 2%-3% of the general population. 1 2 MVP has been associated with an increased risk of arrhythmic complications including atrial/ ventricular arrhythmias and sudden cardiac death (SCD). [3] [4] [5] [6] The prevalence of SCD in MVP has ranged between 1% and 2.5%. 4 6 7 SCD has been reported to be more prevalent among patients with MVP with chordal rupture, flail mitral leaflet and severe mitral regurgitation (MR), suggesting that ventricular volume load may be an important trigger of ventricular arrhythmias. Recently, focal fibrosis was identified in the papillary muscles or inferolateral base on cardiac magnetic resonance (CMR) images with late gadolinium enhancement (LGE) in patients with MVP and complex ventricular arrhythmia (ComVA), SCD or both. 8 9 Focal fibrosis was present even with only mild MR 9 and was thought to be secondary to mechanical tethering of the myocardium by the prolapsing leaflets. Furthermore, increased frequency of complex ventricular ectopic activity has been shown to be associated with a predisposing phenotype of bileaflet MVP with an increased risk for out-of-hospital cardiac arrest. 3 Clinical observations suggest that cases of SCD and MVP do not always fall into the categories of severe MR/flail leaflet or bileaflet MVP with mild regurgitation and focal fibrosis. In addition, the mechanism underlying ventricular arrhythmia associated with chronic left ventricular (LV) volume overload in longstanding severe primary MR is unclear.
Diffuse rather than focal myocardial fibrosis has been reported in MVP-related MR, 10 but its association with ComVA in MVP is yet to be investigated. Myocardial tissue characterisation using T 1 mapping allows for accurate quantitative assessment of diffuse myocardial fibrosis 11 and has been validated by histological studies. 12 Characterisation of the native T 1 of myocardial tissue may be used to detect and assess various cardiomyopathies with prognostic significance. 13 14 The aim of this study was to determine myocardial T 1 in patients with MVP to assess for the presence of diffuse myocardial fibrosis and its association with ComVA.
METHODS

Study population
A query of our institutional electronic CMR database identified 44 patients with MVP referred for clinical CMR from 2006 to 2011. Three studies with poor LGE CMR images were excluded. None of the patients with MVP had coronary artery disease, hypertension or other intrinsic cardiomyopathies. Our control group consisted of 31 consecutively enrolled healthy volunteers free of significant cardiac disease based on clinical and CMR findings. The following baseline clinical and CMR variables were extracted from the electronic clinical database and CMR reports: age, gender, body surface area, systolic/diastolic blood pressure, New York Heart Association functional class, medication use, history of diabetes or tobacco use, estimated glomerular filtration rate (eGFR), contrast dose and time of sequence acquisition. The study was approved by the Beth Israel Deaconess Medical Center Institutional Review Board.
CMR protocol
CMR images were acquired using an Achieva 1.5 T MR whole body scanner (Philips Medical Systems, Best, the Netherlands) equipped with a 32-channel phased array coil. Breath-hold retrospectively ECG-gated cine steady state free processing (SSFP) images were acquired in the 2-chamber (2C) and 4-chamber (4C) horizontal long-axis views, and a short-axis stack covering the entire LV (8 mm slices with 2 mm gaps) as previously described. 15 16 The LV outflow tract long-axis view was obtained by prescribing an image plane perpendicular to the mitral annular major axis centred at the aortic outflow track. In patients with MVP, a contiguous stack of cine SSFP images with 7 mm slice thickness (gap=0 mm) in the outflow tract view were obtained to cover the entire mitral valve. 8 17 Free-breathing, ECG-triggered phase-contrast velocity sequences for ascending aortic flow oriented in the axial plane at the level of the bifurcation of the pulmonary artery were acquired as previously described. 18 Fifteen minutes after administration of 0.2 mmol/kg gadopentetate dimeglumine (Magnevist, Berlex/ Schering AG, Berlin, Germany), ECG-gated breath-hold twodimensional (2D) LGE-CMR was performed in the 2C, 4C and short-axis orientations corresponding to the SSFP cine slices. Myocardial T 1 times were calculated from a breath-hold Look-Locker sequence performed 15-25 min after the injection, with the following imaging parameters: repetition time (TR) 40 ms; echo time (TE) 5.9 ms; flip angle: 15°; 144×144 matrix; field of view (FOV) 400×400 mm; slice thickness 10 mm; echoplanar imaging (EPI) factor: 9. At 20 min after injection, an ECG-gated free breathing, respiratory navigator-gated threedimensional (3D) LGE-CMR scan was obtained. 8 Scan parameters for LGE acquisitions have been previously published. 8 For both 2D and 3D LGE-CMR scans, fat saturation was applied and inversion times were determined using the Look-Locker sequence.
Image analysis
CMR data were analysed using commercially available software (ViewForum R5.1, Philips Medical Systems, Best, the Netherlands). MVP was defined as >2 mm displacement of the mitral leaflets into the left atrium as viewed in the LV outflow tract orientation (figure 1A). 8 17 LV volumes were measured by tracing the end-diastolic and end-systolic LV endocardial contours in each short-axis slice and applying a summation of discs method. The LV ejection fraction (LVEF) was calculated as: 100×(LV end-diastolic volume−LV end-systolic volume)/LV end-diastolic volume. Effective LVEF was calculated as 100×(forward aortic stroke volume/LV end-diastolic volume). LV mass was measured by tracing end-diastolic endocardial and epicardial contours. The papillary muscles were considered part of the ventricular volumes. LV end-diastolic and end-systolic volumes and LV mass were indexed to body size (LVEDVI, LVESVI, LVMI). The MR volume was calculated as the difference between LV stroke volume and the forward aortic flow volume. The MR fraction (MRF) was obtained by dividing MR volume by the LV stroke volume. MR categories were graded as: 0 (none to trace) (<5%); 1+ (mild) (<16%); 2+ (moderate) (16%-25%); 3+ (moderate to severe) (26%-48%) and 4+ (severe) (>48%). 18 Myocardial T 1 times were calculated from Look-Locker sequences with a custom built semi-automated tool (Matlab R2009b, Mathworks, Natick, Massachusetts, USA). The region of interest (ROI) was manually delineated in each T 1 -weighted image of the Look-Locker sequence at the mid-ventricular septum (figure 1B). Apparent T 1 time ðT Ã 1 Þ was estimated by fitting the average T 1 -weighted signal (over each ROI) with a standard 3-parameter fit model of the T 1 recovery signal. 19 T 1 time was finally estimated by correction of apparent T 1 time using the 'Look-Locker correction' approach. 19 The presence of myocardial LGE was determined when part of the myocardial tissue present on the SSFP images was replaced by high signal intensity in the LGE images (either 3D LGE alone or both 2D and 3D LGE) (figure 1C). As there was no evidence of septal LGE (see the Results section), none of the study subjects was excluded from T 1 measurements because of the concomitant presence of LGE.
Arrhythmia analysis
Holter or event monitor arrhythmia data were available within 6 months of CMR in a subset of patients with MVP (n=23). ComVA was defined as grade III or higher by the Lown and Wolf classification. 20 The absence of ComVA was determined by a negative Holter or event monitor, or by the absence of complaints of palpitations or skipped beats and no ambulatory ECG record of ventricular arrhythmias while being regularly followed by local cardiologists.
Statistical analysis
Clinical characteristics of the participants are presented as mean ±SD or median with IQR for normally distributed and skewed continuous variables, respectively. The Shapiro-Wilk test was used to assess for normality. Comparisons between groups were made using Student's t-test or Wilcoxon rank sum test for continuous data and χ 2 or Fisher's exact test for categorical data. figure 3) . LVEDVI was also strongly correlated with T 1 (β, 1.10; 95% CI 0.30 to 1.89; p=0.008), whereas the 10 ( (table 3) .
LGE was found only in the MVP group (table 2) in 11/41 subjects. All 11 patients with MVP with LGE had evidence of papillary muscle fibrosis ( figure 1C ). In addition to papillary muscle involvement, one subject had mid-myocardial LGE of the basal inferolateral wall. None of the patients with MVP had LGE in the interventricular septum.
Ventricular arrhythmia
Among patients with MVP with available information on arrhythmia (n=32, of which 23 were monitor based), there were 14 individuals with ComVA and 18 without ComVA (9 based on negative Holter or event monitor and 9 based on the absence of complaints of palpitations or skipped beats and no ambulatory ECG record of ventricular arrhythmias). Clinical characteristics of the two groups are shown in 
DISCUSSION
In this retrospective study of patients with MVP, we found that MVP was associated with reduced postcontrast T 1 times suggestive of diffuse myocardial fibrosis. In addition, patients with MVP with ComVA had significantly shorter postcontrast T 1 times when compared with patients with MVP without ComVA. Diffuse interstitial derangement was associated with subclinical systolic dysfunction and may represent the mechanism of ComVA in chronic MVP-related MR, even in the absence of focal fibrosis.
Using CMR, a prior investigation has demonstrated abnormal T 1 and diffuse myocardial fibrosis in asymptomatic patients with moderate-to-severe MVP-related MR. 10 Similarly, our patient population includes mostly MVP subjects with ≥2+ MR and our data also highlights the association between lower (although preserved) LVEF and abnormal T 1 . Nevertheless, our study is the first to demonstrate that diffuse interstitial fibrosis is independently associated with ComVA in MVP, even after adjusting for severity of MR, LV cavity size/function and presence of LGE. Only the MVP group with ComVA had a significantly shorter T 1 when compared with controls. This finding further highlights the potential role of diffuse fibrosis in MVP-related arrhythmia.
Patients with MVP in our study sample had predominant bileaflet involvement, a phenotype previously correlated with arrhythmic risk in both clinical and pathological studies. 3 9 In these investigations, the severity of MR was overall mild, and most patients had evidence of focal fibrosis in the inferolateral base or papillary muscles. In contrast, we found that focal fibrosis was present in a minority of patients with MVP and ComVA, and LGE was not the major predictor of arrhythmic risk. Traditionally, increased MR associated with a flail mitral leaflet or ruptured chordae has been reported to increase arrhythmic risk among patients with MVP, [21] [22] as abnormal autonomic tone resulting from LV volume overload may be a predisposing factor to lethal arrhythmia. 23 In our cohort, only the minority of subjects with ≥3+ MR (5/31) had a flail leaflet. Therefore, diffuse myocardial fibrosis may be the substrate of ventricular arrhythmia in the context of significant, longstanding primary MR not driven by a flail leaflet, and outside the rare scenario of mild MR with focal fibrosis.
Whereas lower LVEF was an independent predictor of shorter postcontrast T 1 times in our multivariable analysis, the association of MR with T 1 was borderline significant ( p=0.045). Although subclinical LV systolic dysfunction is most likely secondary to MR, the data are insufficient to completely exclude a primary myopathy among our study subjects. Interestingly, 2 of our 14 patients with ComVA had no or trivial MR, no papillary muscle LGE and T 1 times ≤350. Recently, animal and in vitro studies have demonstrated that overexpression of transforming growth factor (TGF)-β contributes to fibrosis and matrix remodelling in MVP. [24] [25] Whereas focal fibrosis is thought to be secondary to local traction on the papillary muscles and inferolateral wall by the prolapsing leaflets, it is plausible that diffuse fibrosis is rather the consequence of high levels of a profibrotic cytokine, even in the absence of MR. Furthermore, histological studies have demonstrated diffuse myocardial fibrosis in a small subgroup of patients with SCD without clear structural heart disease. 26 Expression of TGF-β was significantly increased compared with controls, suggesting the role of TGF-β as a potential mediator of interstitial remodelling in SCD.
In patients with MVP, premature ventricular contractions or ventricular tachycardia have been shown to arise from the fascicles, LV outflow tract or septal aspect of the mitral annulus on electrophysiological study. 3 As no focal fibrosis has been described by imaging or pathological studies in these sites, it is plausible that the mechanism of arrhythmia differs from the one underlying focal scar in the papillary muscle or the basal inferolateral LV. We can postulate the existence of various mechanisms for ventricular arrhythmia in the MVP population. Focal myocardial fibrosis ( positive LGE) with consequent regions of conduction block may promote re-entry-mediated arrhythmia. In addition, abnormal myocytes in the setting of subclinical myocardial dysfunction and associated interstitial fibrosis (abnormal T 1 ) can manifest spontaneous diastolic depolarisation resulting in abnormal automaticity. Finally, diffuse myocardial fibrosis in the setting of chronic MR, volume loading and LV dilatation could promote enhanced sympathetic tone and triggeredmediated sustained ventricular arrhythmias. Further studies are needed to elucidate the pathophysiology of MVP-related ventricular arrhythmia.
Limitations
Our study has several limitations. First, our sample size is modest, and even smaller when further stratifying by presence or absence of ComVA. Some of the statistically non-significant comparisons may be related to limited power to discern differences. Not all potential predictors of T 1 times could be included in the multivariable regression model due to the small sample size and overfitting. Second, given the retrospective nature of our study, the prevalence of SCD could not be fully ascertained in a longitudinal fashion. ComVA was used as surrogate of arrhythmic risk based on recent literature reporting that ComVA is associated with a predisposing phenotype of bileaflet MVP with an increased risk for out-of-hospital cardiac arrest. 3 Indeed, the majority of our patients with MVP had traditional features of 'malignant' MVP, specifically bileaflet MVP with or without significant MR. Third, our CMR protocol did not include measures of native T 1 or extracellular volume, as these methods were not published at the time of study inception. Although assessment of postcontrast T 1 times is a histologically validated technique, 27 we acknowledge that factors such as heart rate, eGFR and time of sequence acquisition may affect postcontrast T 1 times. In our study, there were no significant differences between MVP subjects and controls with regards to these theoretical confounders (tables 1 and 2) . Lastly, assessment of LGE was qualitative and not quantitative.
Clinical and research implications
Diffuse interstitial derangement may contribute to ComVA in MVP-related MR, even without the presence of focal fibrosis. Clinical follow-up with repeat CMR studies in a larger patient cohort may help clarify if diffuse myocardial fibrosis represents a precursor of focal fibrosis or an independent predictor of SCD. T 1 mapping by CMR may become an additional marker of arrhythmic risk in MVP-related MR and also in early stages of MVP progression without significant MR.
CONCLUSIONS
MVP may be associated with reduced postcontrast T 1 times suggestive of diffuse LV myocardial fibrosis. Diffuse interstitial derangement is associated with subclinical LV systolic dysfunction, and may represent the mechanism of ComVA in MVP-related MR, despite the absence of focal fibrosis. Prospective studies are needed to establish if diffuse myocardial fibrosis is a precursor of focal fibrosis and/or predictor of SCD in this population.
Key messages
What is already known on this subject? Mitral valve prolapse (MVP) is a common valvulopathy affecting 2-3% of the general population and has been associated with an increased risk of arrhythmic complications including atrial/ ventricular arrhythmias and sudden cardiac death (SCD).
What might this study add? MVP may be associated with reduced postcontrast T 1 times suggestive of diffuse left ventricular (LV) myocardial fibrosis. Diffuse interstitial derangement is associated with subclinical LV systolic dysfunction, and may represent the mechanism of complex ventricular arrhythmias in MVP-related mitral regurgitation (MR), despite the absence of focal fibrosis.
How might this impact on clinical practice? T 1 mapping by cardiac magnetic resonance imaging (CMR) may become an additional marker of arrhythmic risk in MVP-related MR. Clinical follow-up with repeat CMR studies in a larger patient cohort may help clarify if diffuse myocardial fibrosis represents a precursor of focal fibrosis or an independent predictor of SCD.
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